Compliance to Multidisciplinary Lifestyle Intervention Decreases Blood Pressure in Patients with Resistant Hypertension: A Cross-Sectional Pilot Study

Hypertension is a common chronic medical condition. Treatment is not satisfactory in a significant proportion of patients with primary hypertension, despite the concurrent use of three or more medications with different mechanisms of action. Such treatment-resistant hypertension is a clinical challenge associated with poor prognosis and needs further investigation. The efficacy of lifestyle changes has not been established yet in patients with resistant hypertension, and educational efforts appear clinically irrelevant in patients who must achieve behavioral changes without supervision. A 6-month multidisciplinary pilot intervention enrolled 50 patients with established resistant hypertension. The aims were: (1) to examine whether intensive and supervised lifestyle changes contribute to decreasing blood pressure in this condition, and (2) to identify which components affect compliance and feasibility. The program provided intensive changes in nutrition, physical exercise, and control of sleep disturbances supervised by nutritionists, physiotherapists, and psychologists. Nurses and pharmacists followed up on adherence to the antihypertensive medication. The primary outcome was 24 h blood pressure control. Data in patients with full compliance (n = 30) indicate that lifestyle modifications in resistant hypertension significantly reduced 24 h both systolic and diastolic blood pressure (p < 0.01), body mass index (p < 0.01), medication burden (p = 0.04), improving physical fitness, and cardiovascular risk markers such as heart rate (p = 0.01) and augmentation index (p = 0.02). The adherence to the intervention was moderate, with an attrition rate of 12%. A modified version reducing visits and explorations will likely improve compliance and can be used to assess the long-term maintenance of these benefits in managing resistant hypertension by diverse healthcare providers.

[1]  M. Fornage,et al.  Polygenic Risk, Midlife Life's Simple 7, and Lifetime Risk of Stroke , 2022, Journal of the American Heart Association.

[2]  L. Aronne,et al.  Tirzepatide Once Weekly for the Treatment of Obesity. , 2022, The New England journal of medicine.

[3]  M. Clozel.  Aprocitentan and the endothelin system in resistant hypertension. , 2022, Canadian journal of physiology and pharmacology.

[4]  R. Arena,et al.  Nonpharmacological Management of Resistant Hypertension , 2021, Current Cardiology Reports.

[5]  W. Kraus,et al.  Effects of Lifestyle Modification on Patients With Resistant Hypertension , 2021, Circulation.

[6]  Michael E. Hall,et al.  Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association , 2021, HYPERTENSION.

[7]  J. Murabito,et al.  Physical activity and fitness in the community: the Framingham Heart Study. , 2021, European heart journal.

[8]  Gretchen A. Stevens,et al.  Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants , 2021, The Lancet.

[9]  S. Woods,et al.  Obesity-associated hyperleptinemia alters the gliovascular interface of the hypothalamus to promote hypertension , 2021, Cell metabolism.

[10]  G. Parati,et al.  2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. , 2021, Journal of hypertension.

[11]  G. Salles,et al.  Associations of the nocturnal blood pressure fall and morning surge with cardiovascular events and mortality in individuals with resistant hypertension. , 2021, Journal of hypertension.

[12]  R. Carey.  The management of resistant hypertension: A 2020 update. , 2020, Progress in cardiovascular diseases.

[13]  Shuzhao Li,et al.  MetaboAnalystR 3.0: Toward an Optimized Workflow for Global Metabolomics , 2020, Metabolites.

[14]  Damiano Rizzoni,et al.  How important is blood pressure variability? , 2020, European heart journal supplements : journal of the European Society of Cardiology.

[15]  A. Pandey,et al.  Resistant hypertension-defining the scope of the problem. , 2019, Progress in cardiovascular diseases.

[16]  C. Lavie,et al.  Impact of therapeutic lifestyle changes in resistant hypertension. , 2019, Progress in cardiovascular diseases.

[17]  G. Mancia,et al.  Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines , 2019, Current Hypertension Reports.

[18]  J. Menéndez,et al.  Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. , 2019, Metabolism: clinical and experimental.

[19]  L. Bortolotto,et al.  Effects of Bariatric Surgery Versus Medical Therapy on the 24-Hour Ambulatory Blood Pressure and the Prevalence of Resistant Hypertension: The GATEWAY Randomized Clinical Trial , 2019, Hypertension.

[20]  J. Bergler-Klein.  What’s new in the ESC 2018 guidelines for arterial hypertension , 2019, Wiener klinische Wochenschrift.

[21]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[22]  K. Kario,et al.  Patterns of ambulatory blood pressure: clinical relevance and application , 2018, Journal of clinical hypertension.

[23]  J. Williamson,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[24]  G. Parati,et al.  Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects , 2018, Integrated blood pressure control.

[25]  S. Julious.  Pilot Studies in clinical research , 2016, Statistical methods in medical research.

[26]  A. Berghold,et al.  Long-term effects of weight-reducing drugs in people with hypertension. , 2016, The Cochrane database of systematic reviews.

[27]  Blair T. Johnson,et al.  Exercise for Hypertension: A Prescription Update Integrating Existing Recommendations with Emerging Research , 2015, Current Hypertension Reports.

[28]  R. Virmani,et al.  Renal denervation therapy for hypertension: pathways for moving development forward. , 2015, Journal of the American Society of Hypertension : JASH.

[29]  S. Yusuf,et al.  Sodium intake and cardiovascular health. , 2015, Circulation research.

[30]  S. Frey,et al.  Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. , 2015, American journal of hypertension.

[31]  Ahmad Esmaillzadeh,et al.  Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: a systematic review and meta-analysis on randomized controlled trials. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[32]  A. Schoenthaler,et al.  Psychosocial Risk Factors for Hypertension: an Update of the Literature , 2014, Current Hypertension Reports.

[33]  Michael Eickenberg,et al.  Machine learning for neuroimaging with scikit-learn , 2014, Front. Neuroinform..

[34]  G. Bakris,et al.  Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study , 2014, Journal of hypertension.

[35]  H. Krum,et al.  Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2013, Circulation.

[36]  G. La Torre,et al.  (In)accuracy of blood pressure measurement in 14 Italian hospitals , 2012, Journal of hypertension.

[37]  W. Elliott,et al.  What is the prevalence of resistant hypertension in the United States? , 2012, Current opinion in cardiology.

[38]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[39]  G. Bakris,et al.  Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. , 2012, Journal of the American Society of Hypertension : JASH.

[40]  L. Manzoli,et al.  Differences in blood pressure by body position (supine, Fowler's, and sitting) in hypertensive subjects. , 2011, American journal of hypertension.

[41]  Stephen D. Persell.  Prevalence of Resistant Hypertension in the United States, 2003–2008 , 2011, Hypertension.

[42]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[43]  A. Benetos,et al.  Heart rate as a risk factor for cardiovascular disease. , 2009, Progress in cardiovascular diseases.

[44]  G. Bray,et al.  Weight loss and blood pressure control (Pro). , 2008, Hypertension.

[45]  Rozemarijn Vliegenthart,et al.  Aortic stiffness is associated with atherosclerosis of the coronary arteries in older adults: the Rotterdam Study , 2006, Journal of hypertension.

[46]  Russell E. Glasgow,et al.  Evaluating the Relevance, Generalization, and Applicability of Research , 2006, Evaluation & the health professions.

[47]  Lawrence W Green,et al.  Public health asks of systems science: to advance our evidence-based practice, can you help us get more practice-based evidence? , 2006, American journal of public health.

[48]  V. Burke,et al.  Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial , 2005, Journal of hypertension.

[49]  J. Joven,et al.  Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. , 2005, The Journal of laboratory and clinical medicine.

[50]  Arya M. Sharma,et al.  Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. , 2004, American journal of hypertension.

[51]  P. Whelton,et al.  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.